Drug
S 892216 PO
S 892216 PO: highest development phase Phase 1, developed by Shionogi. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Shionogi
Trials
| Drug | Phase | Indication |
|---|---|---|
| S-892216-PO NCT07217886 | Phase 1 | Renal Impairment |
Latest
No recent events.
Follow S 892216 PO on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.